Recent Finacing
Recent Raise
Bluejay Therapeutics develops therapies for chronic hepatitis B and D, advancing a human anti‑HBsAg monoclonal antibody (BJT‑778) and an oral HBsAg‑inhibitor small molecule toward clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Bluejay Therapeutics.
